Today is your last day to subscribe to Peacock before they raise their prices: Here are 5 shows that make it worth it
Despite all the cost increases, Peacock does have one pretty big thing going for it: the streamer will feature more live sports than Amazon Prime, Paramount+, Hulu, HBO Max, Apple TV and Netflix combined in 2026, making it a must-have for sports enthusiasts. Currently, you can catch everything from Premier League soccer to WWE, golf, cycling, and much more on the platform.
Not interested in sports? There's one more option available: Peacock is also going to be rolling out a new pricing tier called Peacock Select for $7.99/month that will offer access to all next-day NBC and Bravo entertainment content and older library content (but will not include Peacock original shows and movies or sports).
Despite the significant price jump, we still love a lot of Peacock programming, from shows like The Traitors and Poker Face to it's impressive sports coverage. Here's what you need to know about how to subscribe today and lock in the current annual rate and watch Peacock for less in the coming year.
What to watch on Peacock:
Not sure what to watch with a Peacock subscription? The platform has an extensive library of classic shows like Brooklyn Nine-Nine, The Office and Law & Order, Bravo originals like The Real Housewives franchise and Below Deck, and great movies like Drop and The Bad Guys, and live sports, including WWE, Premier League Soccer and NFL games. Still need more options? Here are five of our favorite shows on Peacock to convince you:
The Traitors
Actor Alan Cumming has assumed his best role yet in Peacock's original reality competition series The Traitors. The premise: Cumming has invited a group of celebrities, from reality stars to politicians and athletes, to his castle in the Scottish highlands where they'll engage in a murder mystery. Cumming secretly names some of his guests as Traitors, and night after night, the Traitors "murder" the remaining contestants, dubbed the Faithfuls, who are then eliminated from the game, while the Faithfuls have to suss out and try and eliminate the Traitors.
There are alliances, there's deception, there are surprise murders – and it's tons of campy fun covered in tartan.
Stream on Peacock
Poker Face
Natasha Lyonne as an amateur detective in a case-of-the-week style mystery show is great TV. In Poker Face, the show created by Knives Out director Rian Johnson, Lyonne stars as Charlie Cale, a woman with the uncanny ability to tell when someone is lying.
Like Murder, She Wrote and Columbo before it, every episode is a who's who of celebrity guests. Season two, which just ended, features appearances from Cynthia Erivo, Giancarlo Esposito, John Mulaney and Sam Richardson, among many others.
Stream on Peacock
The Day of the Jackal
Golden Globes host Nikki Glaser took aim at The Day of the Jackal at this year's award ceremony, saying 'Eddie Redmayne did TV this year. He's nominated for Peacock's The Day of the Jackal. It's about a top-secret elite sniper who no one can see — because he's on Peacock."
Even Redmayne laughed, but don't let the show's quiet presence stop you from checking it out, it's a great crime thriller based on the 1971 novel by Frederick Forsyth. Redmayne stars alongside Moses Ingram in the assassin's cat-and-mouse game and you can binge the whole thing in one go.
Stream on Peacock
Yellowstone
Thanks to a deal struck before Paramount+ even existed in its current form, five seasons of the Paramount Network's hit show Yellowstone, starring Kevin Costner as rancher John Dutton, are available on Peacock. (The show's numerous spinoff prequels are on Paramount+ though, just to keep you on your toes.)
Stream on Peacock
We Are Lady Parts
There are two seasons of the great British sitcom We Are Lady Parts available of Peacock. The show follow a British punk band called Lady Parts, which consists entirely of Muslim women, after their new guitarist, the timid biology student Amina (Anjana Vasan) joins them. As they try to find their audience, Amina struggles to find a comfortable middle ground between her traditional home life and her new life as a musician.
Stream on Peacock
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Why Google should 'walk away' from Waymo
Needham & Company senior media and internet analyst Laura Martin joins Market Domination with Josh Lipton to explain why Alphabet (GOOG, GOOGL) should ditch Waymo and focus on generative artificial intelligence (AI) instead. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Related videos The £70bn pension tax raid Reeves may not be able to resist 10 shares I wouldn't want to hold in a stock market crash After falling 16% in a day, this stock's on my list of shares to buy in August This FTSE 250 trust is easily beating the global index in 2025. Time to buy? Sign in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
EMCOR Group (EME) Sees EPS Surge as Net Income Climbs to US$241 Million
EMCOR Group recently announced a regular quarterly cash dividend of $0.25 per common share, to be paid on July 31, 2025. This steady dividend approach aligns with the company's robust quarterly performance, which saw net income rise to $241 million and EPS increase substantially year-over-year. Additionally, the ongoing share buyback program has strengthened shareholder returns. Despite the broader market's moderate growth of 1.4% over the past week and 17% over the past year, EMCOR's notable share repurchases and solid financial outcomes appear to have amplified investor confidence, contributing to the company's impressive 55% stock price surge last quarter. We've spotted 1 risk for EMCOR Group you should be aware of. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. EMCOR Group's recent announcement of a quarterly dividend and the implementation of its share buyback program underline its commitment to enhancing shareholder returns. Despite a potential downside to the current share price of US$635.06, which exceeds the consensus analyst price target of US$549.57 by 13.46%, these actions could continue to buoy investor confidence. The company's performance over the past five years, with a total return exceeding 844.60%, showcases its robust long-term trajectory. In the last year, EMCOR's share performance exceeded both the broader market's 17.2% and the US Construction industry's 54.2% return, highlighting its strong standing relative to peers. The successful integration of acquisitions and strategic diversification into sectors like data centers and healthcare is anticipated to impact future revenue positively. This, coupled with operational efficiencies and strong revenue collaboration, may reinforce earnings projections. However, EMCOR's earnings forecasts of a 6.2% annual growth rate lag behind the broader market's 14.9% forecast, which could present challenges in meeting broader industry expectations. The company's impressive share price rise of 55% last quarter signals optimism, though its current value being above the target may indicate overvaluation concerns. Nevertheless, the consistent cash flow and healthy margins underscore its potential resilience against margin pressures, supply chain challenges, and other economic uncertainties. As analysts estimate revenue growth to 7.9% annually over the next three years, any tangible improvement in operational metrics could shift the valuation outlook positively. Unlock comprehensive insights into our analysis of EMCOR Group stock in this financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include EME. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY
BioNTech SE and Pfizer recently received a positive recommendation from the European Medicines Agency for marketing authorization of their COVID-19 vaccine, which likely contributed to Pfizer's share price increase of 8% in the last quarter. The company's advancements in COVID-19 vaccine development, alongside other product-related announcements like the XTANDI and BRAFTOVI trial results, added weight to this upward movement. Despite legal challenges and declining earnings, Pfizer's focus on innovation and strategic partnerships like the one with XtalPi possibly countered broader market moves, which saw a smaller 1% increase in the same period. We've identified 3 warning signs for Pfizer that you should be aware of. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent positive recommendation from the European Medicines Agency for the COVID-19 vaccine developed by BioNTech SE and Pfizer has contributed to an 8% increase in Pfizer's share price over the last quarter. This news may provide a temporary boost to Pfizer's revenue and earnings forecasts, especially as the company continues to innovate amidst legal challenges and declining earnings. The authorization could enhance immediate market confidence in Pfizer's product pipeline, impacting future revenue projections positively. Over the past year, Pfizer experienced a total return of 13.78% including dividends, reflecting a challenging period for shareholders. When compared to the broader US market's return of 17.2% over the same period, Pfizer has underperformed, highlighting investor concerns over competitive pressures and revenue growth prospects. The current share price movement toward the analyst consensus price target of $29.23 suggests a cautiously optimistic outlook among some market participants. Analysts' revenue forecasts reflect potential declines due to increased competition for existing products, yet others anticipate that strategic shifts in research focus, especially in oncology, might mitigate future earnings risks. With a modest increase of 8% in shares largely tied to vaccine authorization, it underscores the uncertainty surrounding longer-term performance relative to bearish analyst expectations. Understand Pfizer's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
